BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng C, Lu M, Yang D. CRISPR/Cas9-based tools for targeted genome editing and replication control of HBV. Virol Sin. 2015;30:317-325. [PMID: 26511989 DOI: 10.1007/s12250-015-3660-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Siegrist CM, Kinahan SM, Settecerri T, Greene AC, Santarpia JL. CRISPR/Cas9 as an antiviral against Orthopoxviruses using an AAV vector. Sci Rep 2020;10:19307. [PMID: 33168908 DOI: 10.1038/s41598-020-76449-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yin C, Zhang T, Li F, Yang F, Putatunda R, Young WB, Khalili K, Hu W, Zhang Y. Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS. AIDS 2016;30:1163-74. [PMID: 26990633 DOI: 10.1097/QAD.0000000000001079] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
3 Ren LZ, Peng ZY, Ouyang T, Liu XH, Chen XR, Ye L, Fan JW, Ouyang HS, Pang DX, Bai JY. Subculturing cells have no effect on CRISPR/Cas9-mediated cleavage of UL30 gene in pseudorabies virus. Animal Model Exp Med 2018;1:74-7. [PMID: 30891550 DOI: 10.1002/ame2.12006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Jiang Y, Wu R, Lu J, Dong W, Zhou J, Zhang W, Xin F, Jiang M. Quantitative proteomic analysis to reveal expression differences for butanol production from glycerol and glucose by Clostridium sp. strain CT7. Microb Cell Fact 2021;20:12. [PMID: 33422075 DOI: 10.1186/s12934-021-01508-3] [Reference Citation Analysis]
5 Tang Y, Guo J, Wang T, Zhao K, Liu J, Gao J, Tian Z, An T, Cai X. CRISPR/Cas9‐mediated 2‐sgRNA cleavage facilitates Pseudorabies virus editing. FASEB j 2018;32:4293-301. [DOI: 10.1096/fj.201701129r] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
6 Peng Z, Ouyang T, Pang D, Ma T, Chen X, Guo N, Chen F, Yuan L, Ouyang H, Ren L. Pseudorabies virus can escape from CRISPR-Cas9-mediated inhibition. Virus Res 2016;223:197-205. [PMID: 27507009 DOI: 10.1016/j.virusres.2016.08.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
7 Chen S, Yu X, Guo D. CRISPR-Cas Targeting of Host Genes as an Antiviral Strategy. Viruses 2018;10:E40. [PMID: 29337866 DOI: 10.3390/v10010040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
8 Lee C. CRISPR/Cas9-Based Antiviral Strategy: Current Status and the Potential Challenge. Molecules 2019;24:E1349. [PMID: 30959782 DOI: 10.3390/molecules24071349] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
9 Philips CA, Ahamed R, Abduljaleel JK, Rajesh S, Augustine P. Critical Updates on Chronic Hepatitis B Virus Infection in 2021. Cureus 2021;13:e19152. [PMID: 34733599 DOI: 10.7759/cureus.19152] [Reference Citation Analysis]
10 Meng ZJ, Yang YD. Potential strategies for "cure" of hepatitis B. Shijie Huaren Xiaohua Zazhi 2016; 24(33): 4438-4449 [DOI: 10.11569/wcjd.v24.i33.4438] [Reference Citation Analysis]
11 Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y, Liu H, Li P, Yang C, Yang X. Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front Cell Infect Microbiol. 2017;7:91. [PMID: 28382278 DOI: 10.3389/fcimb.2017.00091] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 9.2] [Reference Citation Analysis]
12 Ebrahimi S, Teimoori A, Khanbabaei H, Tabasi M. Harnessing CRISPR/Cas 9 System for manipulation of DNA virus genome. Rev Med Virol 2019;29:e2009. [PMID: 30260068 DOI: 10.1002/rmv.2009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
13 Sakuma T, Masaki K, Abe-chayama H, Mochida K, Yamamoto T, Chayama K. Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus. Genes Cells 2016;21:1253-62. [DOI: 10.1111/gtc.12437] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]